Target intelligence / Profile preview

Ribosomal protein L7 pseudogene 22 (RPL7P22)

Target
RPL7P22
Molecular classification
Other (Processed pseudogene, derived from ribosomal protein L7)
01

Overview

RPL7P22 is a processed pseudogene in humans, its sequence derived from the functional ribosomal protein L7 gene (RPL7). Unlike its parent gene, RPL7P22 does not encode an active protein and lacks a well-defined biological or molecular function. Processed pseudogenes are generated by reverse transcription and insertion of mRNA back into the genome, and while some pseudogenes are implicated in gene regulation, RPL7P22 is not recognized as a functional pseudogene with disease or therapeutic relevance. In summary, RPL7P22 is not a valid molecular target for therapeutic or diagnostic purposes; it is a processed pseudogene, not a protein nor a functional receptor, enzyme, or other known druggable target class.

Other names
RPL7_6_574RPL7P22
02

Mechanism of action

None; as a pseudogene, it does not possess a known mechanism of action in pharmacology or biology

03

Biological functions

None established; as a pseudogene, RPL7P22 does not have a direct biological function ascribed
04

Disease associations

None specifically attributed; some pseudogenes may impact gene regulation or have subtle effects, but RPL7P22 itself is not documented with a clear disease association
05

Safety considerations

None; it is not a therapeutic or diagnostic target
06

Interacting drugs

None known; no drugs target RPL7P22
07

Biomarkers

None documented; it is not a clinical biomarker

Beyond the preview

Go deeper on Ribosomal protein L7 pseudogene 22 (RPL7P22).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L7 pseudogene 22 (RPL7P22).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call